DaxibotulinumtoxinA

Zelsuvmi's approval for molluscum contagiosum tops Healio's most-read FDA approvals in dermatology for 2024, with other notable approvals including Xeomin, Klisyri, Zoryve, and more.

Dermata Therapeutics (DRMA) has a clinical trial catalyst for its lead asset, DMT310, a topical acne treatment derived from Spongilla lacustris. DMT310 is in phase III trials, with STAR-1 nearing enrollment completion and results expected in Q1 2025. DMT410, using Spongilla technology for botulinum toxin delivery, has completed phase I trials. Dermata reported a Q3 2024 net loss of $3.2 million, with $6.1 million in cash expected to fund operations through Q1 2025.

Dr. Ran Y. Rubinstein selected to train professionals on FDA-approved BOTOX® Cosmetic for platysma bands in Montvale, NJ, enhancing skills in non-surgical neck rejuvenation.

Botox, originally used for crossed eyes, now treats migraines, excessive sweating, and more. It blocks nerve signals to muscles, offering relief but requiring frequent injections. Multiple brands exist, each with potential for unique responses. Training and expertise are crucial to avoid side effects.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.

Serotonin Centers launches new St. Petersburg location offering personalized wellness solutions, including aesthetic enhancement, hormone balancing, weight loss, and muscle development.

AbbVie lost $40 billion in market value after its experimental drug emraclidine failed two clinical trials for schizophrenia. Despite the setback, AbbVie remains focused on neuroscience and has a diverse portfolio of brain medicines. The failure of emraclidine removes a competitive threat for Bristol Myers' Cobenfy, an approved antipsychotic.

Javascript not activated